π‐Extended Helical Nanographenes: Synthesis and Photophysical Properties of Naphtho[1,2‐
<i>a</i>
]pyrenes**
作者:Wesley A. Chalifoux、Paban Sitaula、Ryan J. Malone、Giovanna Longhi、Sergio Abbate、Eva Gualtieri、Andrea Lucotti、Matteo Tommasini、Roberta Franzini、Claudio Villani、Vincent J. Catalano
DOI:10.1002/ejoc.202101466
日期:2022.5.6
A mild Lewis acid-catalyzed double alkyne benzannulation reaction onto a phenathrene moiety results in the rapid synthesis of π-extended [4]helicene hybrids. Substitution of the cove region results in increased inversion barriers and allows for separation and study of the enantiomers by circular dichroism.
2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
申请人:Chau Anh
公开号:US20090075998A1
公开(公告)日:2009-03-19
The invention encompasses novel compounds of Formula I
or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.
2-(Phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
申请人:Chau Anh
公开号:US20070208017A1
公开(公告)日:2007-09-06
The invention encompasses novel compounds of Formula I
or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.
The present invention is directed to a method for treating or preventing a neoplasia in a human patient in need of such treatment comprising administering to the patient a compound that inhibits microsomal prostaglandin E synthase-1 in an amount that is effective for treating or preventing the neoplasia.